Specialty Pharmacy

Study finds that treating hepatitis C reduced the risk of developing the signs and symptoms of Parkinson disease.

New high-cost gene therapies are pushing health care providers to explore new methods to help the US health care system to fund specialty drugs.

Top news of the day across the health care landscape.

Researches seeking to eliminate HIV are close enough to see the finish line, but with no idea how far away they are from a cure.

Transcranial direct current stimulation shows promise in addressing fatigue in patients with multiple sclerosis.

The FDA has approved dasatinib (Sprycel) tablets in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] is the first and only antidote for patients treated with rivaroxaban or apixaban, when anticoagulation reversal is needed.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, talks about how different providers must work together to ensure the success of a value-based care system.

Study finds at least a 1.5-fold difference between states with lowest and highest proportions of cancers related to obesity.

Top news of the day across the health care landscape.

Survivors of Hodgkin Lymphoma have higher incidence rates of breast, lung, colorectal, and thyroid cancer later in life compared with the general population, new study says.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, discusses the collaborative approach taken at his clinic in the management and treatment of patients with hemophilia.

Looking ahead, there are a plethora of promising new treatments for a range of specialty conditions in the 2019 drug pipeline.

Top news of the day across the health care landscape.

While there were many notable approvals, we’ve rounded up a list of 10 newly-approved therapies to know from 2018.

Here are the top articles from our hepatitis coverage of the year.

Top news of the day across the health care landscape.

More than 702,000 Americans died from drug overdoses from 1999 to 2017–about 10% of them in 2017 alone.

Drug approvals and emerging research highlighted the news in the HIV space this past year.

Researchers aimed to better understand the different ways that breast cancer avoids immune system detection.

Newsworthy moments, groundbreaking research, and a continuation of industry trends highlight the most read articles on Specialty Pharmacy Times® of 2018.

From clinical trials evaluating treatments to studies unearthing new discoveries about the disease's mechanism, these were some of the top newsworthy moments in multiple sclerosis research in 2018.

The FDA has approved tagraxofusp-erzs (Elzonris, Stemline Therapeutics) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, aged 2 years and older.

Ravulizumab (Ultomiris, Alexion) is the first long-acting complement inhibitor approved for the treatment of paroxysmal nocturnal hemoglobinura.

Cigna recently announced the completion of its $54-billion purchase of Express Scripts.

Top news of the week from Specialty Pharmacy Times.

The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients, aged 1 month to 21 years.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

Biosimilars present a cost-saving opportunity for the health care system, but significant challenges inhibit uptake in the US market.